Imaging of parasites is central to diagnosis of many parasitic diseases and has thus far
played an important role in the development of antiparasitic strategies. The development of …

Globally, schistosomiasis threatens more than 700 million lives, mostly children, in poor
localities of tropical and sub-tropical areas with morbidity due to acute and chronic …

Although its efficiency against all Schistosoma species, praziquantel (PZQ) shows low
efficacy against schistosomula and juvenile stages. The potential for development of …

Schistosomiasis remains one of the world's leading health concerns, affecting millions. The
granulomatous reaction is the most significant immunopathological change associated with …

Schistosomiasis is a widespread human parasitic disease currently affecting over 200
million people. Chemotherapy for schistosomiasis relies exclusively on praziquantel …

Schistosomiasis is still a major health problem affecting nearly 250 million people worldwide
and causes approximately 280,000 deaths per year. The disease causes a serious …

Due to the development of praziquantel (PZQ) schistosomes resistant strains, the discovery
of new antischistosomal agents is of high priority in research. This work reported the in vitro …

World Health Organization (WHO) has approved only one treatment for schistosomiasis,
praziquantel (PZQ), but some poor efficacy was noticed in patients during the early stage of …

Background Schistosomiasis is a debilitating neglected tropical disease that affects
approximately 190 million people around the world. Praziquantel (PZQ) is the only drug …

Leishmaniasis is a neglected disease caused by protozoa of the genus Leishmania, which
causes different clinical manifestations. Drugs currently used in the treatment such as …